Kymeris Therapeutics

9:00 AM - 9:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Kymeris Therapeutics is late Discovery Stage firm with an effective Solid Cancer Immunotherapy platform. In 3 years, we achieved Proofs of Principle in 5 pre-clinical murine models of solid cancer, including one preventing metastasis in an I.V. melanoma challenge.

Highly potent in inducing Th-I (Cellular Immunity), the platform shows reprogramming of the Tumor Microenvironment ("Cold"​ tumors turn "hot"​). It has been also been engineered to target cancer, express or secrete proteins of therapeutic interest.

Research in France guided by US ex-head of oncology at 3 major pharma. With support from top US immune-oncology luminaries, we are poised to select our lead pre-IND candidate and also seek co-development to vector/combine with a partner's agent.

Our platform is based on non-pathogenic organisms (only recently identified) to which Kymeris has exclusive global rights in oncology.

We plan future Clinical Development in the USA and seek investors and potential partn
Company Type:
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
pending
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided